| Literature DB >> 23110724 |
Jan Ac Hontelez1, Marie-Louise Newell, Ruth M Bland, Kristen Munnelly, Richard J Lessells, Till Bärnighausen.
Abstract
BACKGROUND: Although access to life-saving treatment for patients infected with HIV in South Africa has improved substantially since 2004, treating all eligible patients (universal access) remains elusive. As the prices of antiretroviral drugs have dropped over the past years, availability of human resources may now be the most important barrier to achieving universal access to HIV treatment in Africa. We quantify the number of HIV health workers (HHWs) required to be added to the current HIV workforce to achieve universal access to HIV treatment in South Africa, under different eligibility criteria.Entities:
Year: 2012 PMID: 23110724 PMCID: PMC3529683 DOI: 10.1186/1478-4491-10-39
Source DB: PubMed Journal: Hum Resour Health ISSN: 1478-4491
Baseline characteristics of the time and motion data
| Observation days, n | 13 | 5 | 4 | 4 |
| Observation period | 12 August to 1 September | 19 to 26 August | 12 to 18 August | 27 August to 1 September |
| | | | | |
| Nurse | 6 | 2 | 2 | 2 |
| Counselor | 4 | 2 | 1 | 1 |
| Doctor | 3 | 1 | 1 | 1 |
| Total patients observed, n | 334 | 115 | 120 | 99 |
| | | | ||
| Overall | 6.3 | 5.2 | 7.3 | 4.9 |
| Nurse | 7.1 | 5.2 | 7.3 | 5.3 |
| Counselor | 5.8 | 5.3 | 6.7 | 5.8 |
| Doctor | 5.4 | 5.1 | 7.7 | 3.4 |
| | | | ||
| | | | | |
| Overall | 83 | 86 | 87 | 76 |
| Nurse | 83 | 84 | 83 | 82 |
| Counselor | 74 | 87 | 82 | 20 |
| Doctor | 92 | 91 | 94 | 89 |
| Indirect patient contactb | | | | |
| Overall | 9 | 7 | 9 | 10 |
| Nurse | 9 | 8 | 13 | 6 |
| Counselor | 13 | 6 | 8 | 44 |
| Doctor | 4 | 8 | 4 | 3 |
| | | | | |
| Overall | 9 | 7 | 5 | 14 |
| Nurse | 9 | 9 | 3 | 12 |
| Counselor | 13 | 7 | 10 | 36 |
| Doctor | 4 | 2 | 2 | 8 |
| | | | ||
| Overall | 12 (9 to 14) | 14 (9 to 18) | 11 (8 to 13) | 10 (5 to 16) |
| Nurse | 10 (6 to 13) | 12 (6 to 18) | 12 (7 to 17) | 7 (1 to 12) |
| Counselor | 14 (9 to 19) | 15 (7 to 23) | 8 (5 to 11) | 43 (2 to 83) |
| Doctor | 13 (9 to 16) | 15 (2 to 27) | 15 (11 to 18) | 9 (7 to 11) |
HHW, HIV health worker.
Direct patient contact included activities such as talking to patients, venepuncture, physical examination, and prescribing medication.
bIndirect patient contact included activities such as consultations, meetings with colleagues, and administrative work.
c’Other’ consisted of breaks and idle time between patients.
Coverage indicators South Africaa
| | |||
| Receiving ART, n | 971,566 | NA | NA |
| Needing ART, n | | | |
| CD4 ≤200 | 1,700,000 | 1,500,000 | 2,000,000 |
| CD4 ≤350 (TB or pregnant); CD4 ≤200 (all other HIV-infected people) b | 1,925,000 | 1,750,000 | 2,200,000 |
| CD4 ≤350 | 2,600,000 | 2,500,000 | 2,800,000 |
| CD4 ≤500c | 4,100,000 | 3,950,000 | 4,340,000 |
| All HIV-positive people | 5,600,000 | 5,400,000 | 5,900,000 |
| Coverage,% | | | |
| CD4 ≤200 | 56 | 65 | 48 |
| CD4 ≤350 (TB or pregnant); CD4 ≤200 (all other HIV-infected people)b | 50 | 56 | 44 |
| CD4 ≤350 | 37 | 39 | 35 |
| CD4 ≤500c | 24 | 25 | 22 |
| All HIV-positive people | 17 | 18 | 16 |
| Needed to initiate ART, n | | | |
| CD4 ≤200 | 728,434 | 528,434 | 1,028,434 |
| CD4 ≤350 (TB or pregnant); CD4 ≤200 (all other HIV-infected people)b | 952,444 | 778,444 | 1,228,444 |
| CD4 ≤350 | 1,628,434 | 1,528,434 | 1,828,434 |
| CD4 ≤500c | 3,128,434 | 2,978,434 | 3,368,434 |
| All HIV-positive people | 4,628,434 | 4,428,434 | 4,928,434 |
ART, antiretroviral therapy; CD4, CD4 cell count (expressed in cells/μl;); NA, not applicable.
aSource: WHO Towards Universal Access report 2010 [23].
bWe assumed 25% of those with CD4 cell counts of 200 to 350 μl to be eligible because of pregnancy or co-infection with tuberculosis.
cNumber of people estimated to be between those eligible at 350 cells/μl or lower and those eligible under the strategy of ART for all HIV-infected people.
Human resources needs and salary costs for initiating all those eligible for antiretroviral therapy (ART) and maintaining them on ART for one year, under different treatment strategies
| | | | | | | | | |
| CD4 ≤200 | 12 (8 to 16) | 1.0 (0.7 to 1.3) | 20 (12 to 28) | 1.7 (1.0 to 2.3) | 2 (1 to 2) | 0.1 (0.1 to 0.2) | 12 (8 to 16) | 12 (8 to 16) |
| CD4 ≤350 (TB or pregnant); CD4 ≤200 (all other HIV-infected people) | 15 (10 to 20) | 1.3 (0.9 to 1.7) | 27 (16 to 37) | 2.2 (1.4 to 3.1) | 2 (1 to 3) | 0.2 (0.1 to 0.2) | 15 (10 to 20) | 15 (10 to 20) |
| CD4 ≤350 | 26 (18 to 35) | 2.2 (1.5 to 2.9) | 45 (28 to 63) | 3.8 (2.3 to 5.2) | 3 (2 to 4) | 0.3 (0.2 to 0.4) | 26 (18 to 35) | 26 (18 to 35) |
| CD4 ≤500 | 51 (34 to67) | 4.2 (2.8 to 5.6) | 87 (53 to 121) | 7.3 (4.4 to 10.1) | 6 (5 to 8) | 0.5 (0.4 to 0.7) | 51 (34 to67) | 51 (34 to67) |
| All HIV-positive people | 74 (50 to 99) | 6.2 (4.2 to 8.2) | 129 (79 to 179) | 10.7 (6.6 to 14.9) | 9 (7 to 12) | 0.8 (0.6 to 1.0) | 74 (50 to 99) | 74 (50 to 99) |
| | | | | | | | | |
| CD4 ≤200 | 17 (11 to 22) | 1.4 (0.9 to 1.8) | 29 (17 to 40) | 2.4 (1.5 to 3.3) | 2 (1 to 3) | 0.2 (0.1 to 0.2) | 17 (11 to 22) | 17 (11 to 22) |
| CD4 ≤350 (TB or pregnant); CD4 ≤200 (all other HIV-infected people) | 20 (13 to 26) | 1.6 (1.1 to 2.2) | 34 (21 to 48) | 2.8 (1.7 to 4.0) | 3 (2 to 3) | 0.2 (0.2 to 0.3) | 20 (13 to 26) | 20 (13 to 26) |
| CD4 ≤350 | 30 (20 to 39) | 2.5 (1.7 to 3.3) | 51 (31 to 71) | 4.2 (2.6 to 5.9) | 4 (3 to 5) | 0.3 (0.2 to 0.4) | 30 (20 to 39) | 30 (20 to 39) |
| CD4 ≤500 | 54 (37 to 72) | 4.5 (3.0 to 6.0) | 94 (57 to 130) | 7.8 (4.8 to 10.9) | 7 (5 to 9) | 0.6 (0.4 to 0.7) | 54 (37 to 72) | 54 (37 to 72) |
| All HIV-positive people | 80 (54 to 106) | 6.6 (4.5 to 8.8) | 137 (84 to 191) | 11.4 (7.0 to 15.9) | 10(7 to 13) | 0.8 (0.6 to 1.1) | 80 (54 to 106) | 80 (54 to 106) |
| | | | | | | | | |
| CD4 ≤200 | 9 (6 to 11) | 0.7 (0.5 to 1.0) | 15 (9 to 20) | 1.2 (0.7 to 1.7) | 1 (1 to 1) | 0.1 (0.1 to 0.1) | 9 (6 to 11) | 9 (6 to 11) |
| CD4 ≤350 (TB or pregnant); CD4 ≤200 (all other HIV-infected people) | 13 (8 to 17) | 1.1 (0.7 to 1.4) | 22 (13 to 30) | 1.8 (1.1 to 2.5) | 2 (2 to 3) | 0.1 (0.1 to 0.2) | 13 (8 to 17) | 13 (8 to 17) |
| CD4 ≤350 | 25 (17 to 33) | 2.1 (1.4 to 2.7) | 43 (26 to 59) | 3.5 (2.2 to 4.9) | 3 (2 to 4) | 0.3 (0.2 to 0.3) | 25 (17 to 33) | 25 (17 to 33) |
| CD4 ≤500 | 48 (32 to 64) | 4.0 (2.7 to 5.3) | 83 (51 to 115) | 6.9 (4.2 to 9.6) | 6 (4 to 8) | 0.5 (0.4 to 0.7) | 48 (32 to 64) | 48 (32 to 64) |
| All HIV-positive people | 72 (48 to 95) | 6.0 (4.0 to 7.9) | 123 (75 to 171) | 10.3 (6.2 to 14.3) | 9 (6 to 12) | 0.8 (0.5 to 1.0) | 72 (48 to 95) | 72 (48 to 95) |
CD4, CD4 cell count (expressed as cells/μl); FTE, full-time equivalent; ZAR = South African rand.
aCurrent total expenditure: estimate of the total amount spent on preventing and treating HIV in South Africa in 2009 (ZAR 14 billion) [66].
bFor the calculations of the point, high, and low estimates, we used the point, high, and low estimates of the number of people living with HIV in South Africa published in the most recent UNAIDS world AIDS report [66].
Sensitivity analysis of human resources needs and salary costs for initiating all those eligible for antiretroviral therapy (ART) and maintaining them on ART for one year, under different treatment strategies
| | ||||||||
|---|---|---|---|---|---|---|---|---|
| | | | | | | | ||
| CD4 ≤200 | 10 (7 to 13) | 0.8 (0.6 to 1.1) | 17 (10 to 24) | 1.4 (0.9 to 2.0) | 1 (1 to 1) | 0.1 (0.1 to 0.1) | 339 (223 to 456) | 2 (2 to 3) |
| CD4 ≤350 (TB or pregnant); CD4 ≤200 (all other HIV-infected people) | 13 (9 to 17) | 1.1 (0.7 to 1.4) | 22 (14 to 31) | 1.9 (1.1 to 2.6) | 1 (1 to 2) | 0.1 (0.1 to 0.1) | 445 (292 to 597) | 3 (2 to 4) |
| CD4 ≤350 | 22 (15 to 29) | 1.8 (1.2 to 2.3) | 38 (23 to 53) | 3.2 (1.9 to 4.4) | 2 (2 to 3) | 0.2 (0.1 to 0.2) | 760 (499 to 1,019) | 5 (4 to 7) |
| CD4 ≤500 | 42 (29 to 56) | 3.5 (2.4 to 4.7) | 73 (45 to 101) | 6.1 (3.7 to 8.4) | 4 (3 to 6) | 0.4 (0.3 to 0.5) | 1,459 (959 to 1,959) | 10 (7 to 14) |
| All HIV-positive people | 63 (42 to 84) | 5.2 (3.5 to 7.0) | 108 (66 to 150) | 9.0 (5.5 to 12.5) | 6 (5 to 8) | 0.5 (0.4 to 0.7) | 2,159 (1,419 to 2,899) | 15 (10 to 21) |
| | | | | | | | ||
| CD4 ≤200 | 15 (10 to 20) | 1.2 (0.8 to 1.6) | 28 (17 to 38) | 2.3 (1.4 to 3.2) | 2 (2 to 3) | 0.2 (0.2 to 0.3) | 559 (369 to 749) | 4 (3 to 5) |
| CD4 ≤350 (TB or pregnant); CD4 ≤200 (all other HIV-infected people) | 19 (13 to 26) | 1.6 (1.1 to 2.2) | 36 (22 to 50) | 3.0 (1.8 to 4.2) | 3 (2 to 4) | 0.3 (0.2 to 0.4) | 732 (483 to 981) | 5 (3 to 7) |
| CD4 ≤350 | 33 (22 to 44) | 2.8 (1.9 to 3.7) | 62 (38 to 86) | 5.1 (3.1 to 7.1) | 6 (4 to 7) | 0.5 (0.3 to 0.6) | 1,250 (825 to 1,675) | 9 (6 to 12) |
| CD4 ≤500 | 63 (43 to 85) | 5.3 (3.6 to 7.1) | 118 (72 to 165) | 9.9 (6.0 to 13.7) | 11 (8 to 14) | 0.9 (0.6 to 1.1) | 2,401 (1,584 to 3,218) | 17 (11 to 23) |
| All HIV-positive people | 94 (63 to 126) | 7.9 (5.3 to 10.5) | 175 (107 to 243) | 14.6 (8.9 to 20.3) | 16 (11 to 20) | 1.3 (0.9 to 1.7) | 3,552 (2,344 to 4,762) | 25 (17 to 34) |
| | | | | | | | ||
| CD4 ≤200 | 11 (8 to 15) | 1.0 (0.6 to 1.3) | 20 (12 to 27) | 1.6 (1.0 to 2.3) | 1 (1 to 2) | 0.1 (0.1 to 0.2) | 404 (266 to 541) | 3 (2 to 4) |
| CD4 ≤350 (TB or pregnant); CD4 ≤200 (all other HIV-infected people) | 15 (10 to 20) | 1.2 (0.8 to 1.6) | 26 (16 to 36) | 2.1 (1.3 to 3.0) | 2 (1 to 3) | 0.2 (0.1 to 0.2) | 524 (345 to 702) | 4 (2 to 5) |
| CD4 ≤350 | 25 (17 to 33) | 2.1 (1.4 to 2.7) | 43 (26 to 59) | 3.5 (2.2 to 4.9) | 3 (2 to 4) | 0.3 (0.2 to 0.3) | 871 (574 to 1,168) | 6 (4 to 8) |
| CD4 ≤500 | 45 (30 to 59) | 3.7 (2.5 to 4.9) | 77 (47 to 107) | 6.4 (3.9 to 8.9) | 6 (4 to 7) | 0.5 (0.3 to 0.6) | 1,576 (1,039 to 2,113) | 11 (7 to 15) |
| All HIV-positive people | 62 (42 to 82) | 5.2 (3.5 to 6.9) | 107 (65 to 149) | 8.9 (5.5 to 12.4) | 8 (6 to 10) | 0.7 (0.5 to 0.8) | 2,196 (1,449 to 2,946) | 16 (10 to 21) |
CD4 = CD4 cell count (expressed as cells/μl); FTE, full-time equivalent; ZAR = South African rand.
The underlying number of patients needing treatment are based on the WHO-reported ART treatment coverage in South Africa [23] and UNAIDS-reported point estimate of the total number of people infected with HIV [66], see Table 2.
aCurrent total expenditure: estimate of the total amount spent on preventing and treating HIV in South Africa in 2009 (ZAR 14 billion) [66].
Effect of alternative models of antiretroviral therapy (ART) delivery on the HIV health worker-to-patient ratio and overall salary costs for universal access to HIV treatment in South Africa
| 1.2 (0.8 to 1.6) | 2.1 (1.3 to 2.9) | 0.2 (0.1 to 0.2) | NA | |
| | | | ||
| Every 2 months | 0.7 (0.5 to 0.9) | 1.2 (0.7 to 1.6) | 0.2 (0.1 to 0.2) | 36 |
| Every 3 months | 0.5 (0.3 to 0.6) | 0.8 (0.5 to 1.1) | 0.2 (0.1 to 0.2) | 50 |
| Every 4 months | 0.3 (0.2 to 0.5) | 0.6 (0.4 to 0.8) | 0.2 (0.1 to 0.2) | 57 |
| | | | ||
| Every 2 months | 0.7 (0.5 to 0.9) | 2.1 (1.3 to 2.9) | 2.0 (1.5 to 2.6) | 24 |
| Every 3 months | 0.5 (0.3 to 0.6) | 2.1 (1.3 to 2.9) | 2.0 (1.5 to 2.6) | 33 |
| Every 4 months | 0.3 (0.2 to 0.5) | 2.1 (1.3 to 2.9) | 2.0 (1.5 to 2.6) | 38 |
| 1.3 (1.0 to 1.7) | 2.1 (1.3 to 2.9) | NA | 7 | |
NA = not applicable.